Real-world data on commercial long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results: Findings from a University Hospital in Paris, France

被引：0
|
作者：
Ferre, V. M. [1 ,2 ]
Serris, A. [1 ,3 ]
Le Hingrat, Q. [1 ,2 ]
Bachelard, A. [3 ]
Charpentier, C. [1 ,2 ]
Exarchopoulos, M. [3 ]
Digumber, M. [3 ]
Damond, F. [1 ,2 ]
Louni, F. [3 ]
Phung, B. [3 ]
Landman, R. [1 ,4 ]
Yazdanpanah, Y. [4 ]
Descamps, D. [1 ,2 ]
Joly, V. [1 ,4 ]
Peytavin, G. [1 ,5 ]
Ghosn, J. [1 ,4 ]
机构：
[1] Univ Paris Cite, INSERM, IAME, UMR 1137, Paris, France
[2] Hop Bichat Claude Bernard, AP HP, Dept Virol, Paris, France
[3] Hop Bichat Claude Bernard, AP HP, Dept Infect Dis, Paris, France
[4] Hop Bichat Claude Bernard, Dept Infect Dis, Paris, France
[5] Dept Pharmacol, Dept Infect Dis, Hop Bichat Claude Bernard, Paris, France
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
878
引用
收藏
页码：160 / 161
页数：2
相关论文
共 18 条
  • [1] Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results
    Serris, Alexandra
    Ferre, Valentine Marie
    Le Hingrat, Quentin
    Bachelard, Antoine
    Charpentier, Charlotte
    Exarchopoulos, Marina
    Damond, Florence
    Phung, Bao-Chau
    Landman, Roland
    Yazdanpanah, Yazdan
    Descamps, Diane
    Joly, Veronique
    Peytavin, Gilles
    Ghosn, Jade
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (11) : 2932 - 2938
  • [2] Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results (Sept, dkae308, 2024)
    Serris, Alexandra
    Ferre, Valentine Marie
    Le Hingrat, Quentin
    Bachelard, Antoine
    Charpentier, Charlotte
    Exarchopoulos, Marina
    Damond, Florence
    Phung, Bao-Chau
    Landman, Roland
    Yazdanpanah, Yazdan
    Descamps, Diane
    Joly, Veronique
    Peytavin, Gilles
    Ghosn, Jade
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (12) : 3370 - 3370
  • [3] Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)
    John, M.
    Williams, L.
    Nolan, G.
    Bonnett, M.
    Castley, A.
    Nolan, D.
    HIV MEDICINE, 2024, 25 (08) : 935 - 945
  • [4] Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
    Michael G. Sension
    Laurence Brunet
    Ricky K. Hsu
    Jennifer S. Fusco
    Quateka Cochran
    Christine Uranaka
    Gayathri Sridhar
    Vani Vannappagari
    Jean Van Wyk
    Lewis McCurdy
    Michael B. Wohlfeiler
    Gregory P. Fusco
    Infectious Diseases and Therapy, 2023, 12 : 2807 - 2817
  • [5] Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: Efficacy and tolerance during the first 72 weeks
    Psomas, C. K.
    Halfon, P.
    Salnikova, M.
    Khiri, H.
    Tichadelle, F.
    Allemand, J.
    Neant, N.
    Solas, C.
    Philibert, P.
    HIV MEDICINE, 2023, 24 : 81 - 82
  • [6] Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures
    Thoueille, Paul
    Cavassini, Matthias
    Guidi, Monia
    Buclin, Thierry
    Girardin, Francois R.
    Decosterd, Laurent A.
    Marzolini, Catia
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (02):
  • [7] Cabotegravir plus Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
    Sension, Michael G.
    Brunet, Laurence
    Hsu, Ricky K.
    Fusco, Jennifer S.
    Cochran, Quateka
    Uranaka, Christine
    Sridhar, Gayathri
    Vannappagari, Vani
    Van Wyk, Jean
    Mccurdy, Lewis
    Wohlfeiler, Michael B.
    Fusco, Gregory P.
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (12) : 2709 - 2724
  • [8] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
    Rizzardini, Giuliano
    Overton, Edgar T.
    Orkin, Chloe
    Swindells, Susan
    Arasteh, Keikawus
    Gorgolas Hernandez-Mora, Miguel
    Pokrovsky, Vadim
    Girard, Pierre-Marie
    Oka, Shinichi
    Andrade-Villanueva, Jaime F.
    Richmond, Gary J.
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Griffith, Sandy
    Harrington, Conn M.
    Hudson, Krischan J.
    St Clair, Marty
    Talarico, Christine L.
    Patel, Parul
    Cutrell, Amy
    Van Eygen, Veerle
    D'Amico, Ronald
    Mrus, Joseph M.
    Wu, Sterling
    Ford, Susan L.
    Chow, Ken
    Roberts, Jeremy
    Wills, Angela
    Walters, Nicola
    Vanveggel, Simon
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Smith, Kimberly Y.
    Spreen, William R.
    Margolis, David A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
  • [9] Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
    Iannone, Valentina
    Rossotti, Roberto
    Bana, Nicholas Brian
    Cavazza, Gabriele
    D'Amico, Federico
    Lombardi, Francesca
    Salvo, Pierluigi Francesco
    Baldin, Gianmaria
    Di Giambenedetto, Simona
    Bernacchia, Dario
    Pagani, Gabriele
    Borghetti, Alberto
    Rusconi, Stefano
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [10] Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting
    Konishi, Keiji
    Onozuka, Daisuke
    Okubo, Moeka
    Kasamatsu, Yu
    Kutsuna, Satoshi
    Shirano, Michinori
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
12